The director of NIAID is appointed by the head of the NIH, who must be approved by the Senate. Directors have broad ...

This story is part of our ongoing “First Steps” series, where we share extraordinary stories of men who transformed their bodies, minds, and lives with a focus on the first steps it took them to get ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

This story was originally published in ProPublica, a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story ...

Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat ...

Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment ...

Big bank profits surged in the fourth quarter and Wall Street roared back to life, with net income rising 50% at JPMorgan Chase and more than doubling at Goldman Sachs. Hindenburg Research founder ...

Eli Lilly (NYSE:LLY) has received FDA approval for its drug Omvoh, also known as mirikizumab-mrkz, for the treatment of ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...

Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval. 2 "The burden of Crohn's disease on patients' ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...